Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.46 |
| ▸ | CYP4F2 | P78329 | 2/20 | 0.45 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.45 |
| ▸ | AKT1 | P31749 | 1/20 | 0.44 |
| ▸ | PAM | P19021 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | RECQL | P46063 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6210514 | 0.82 | MEN1 (0.58) | POLBCYP4F2CYP4A11ALDH1A1TSHR | |
| SCHEMBL2877458 | 0.81 | CYP4F2 (0.64) | CYP4F2CYP4A11AKT1PAMALDH1A1 | |
| SCHEMBL2877454 | 0.81 | CYP4F2 (0.64) | CYP4F2CYP4A11AKT1PAMALDH1A1 | |
| SCHEMBL27649582 | 0.81 | AKT1 (0.57) | POLBAKT1ALDH1A1TSHRMEN1 | |
| SCHEMBL18334864 | 0.81 | PTGS2 (0.55) | CYP4F2CYP4A11ALDH1A1TSHRMEN1 | |
| SCHEMBL6208553 | 0.79 | MAOB (0.40) | POLBPAMALDH1A1TSHRMEN1 | |
| SCHEMBL1380798 | 0.79 | PTPRC (0.40) | PAMALDH1A1TSHRMEN1KMT2A | |
| SCHEMBL27488368 | 0.79 | CYP4F2 (0.46) | POLBCYP4F2CYP4A11AKT1ALDH1A1 | |
| Hydrazine SCHEMBL30778291 | 0.78 | CYP4F2 (0.60) | CYP4F2CYP4A11AKT1PAMALDH1A1 | |
| SCHEMBL13908714 | 0.78 | CYP4F2 (0.65) | POLBCYP4F2CYP4A11PAMALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2002040449-A1 | DIHYDROISOQUINOLINES AS NOVEL PHOSPHODIESTERASE INHIBITORS | ALTANA PHARMA AG (DE) | 2002-05-23 | — | — | WO | claimed |
| EP-4275752-A2 | TREATMENT OF ADDICTION AND IMPULSE-CONTROL DISORDERS USING PDE7 INHIBITORS | Omeros Corporation (US) | 2023-11-15 | — | — | EP | disclosed |
| US-20230110784-A1 | TREATMENT OF ADDICTION AND IMPULSE-CONTROL DISORDERS USING PDE7 INHIBITORS | OMEROS CORPORATION | 2023-04-13 | — | — | US | disclosed |
| CN-115192711-A | Use of PDE7 inhibitors for the treatment of movement disorders | 奥默罗斯公司 | 2022-10-18 | — | — | CN | disclosed |
| CN-114984229-A | Treatment of addiction and impulse control disorders using PDE7 inhibitors | 奥默罗斯公司 | 2022-09-02 | — | — | CN | disclosed |
| US-11207275-B2 | Treatment of addiction and impulse-control disorders using PDE7 inhibitors | OMEROS CORPORATION (US) | 2021-12-28 | — | — | US | disclosed |
| CN-112168972-A | Treatment of addiction and impulse control disorders using PDE7 inhibitors | 奥默罗斯公司 | 2021-01-05 | — | — | CN | disclosed |
| CN-104758291-B | Use of PDE7 inhibitors for the treatment of movement disorders | 奥默罗斯公司 | 2020-03-03 | — | — | CN | disclosed |
| US-20190183824-A1 | USE OF PDE7 INHIBITORS FOR THE TREATMENT OF MOVEMENT DISORDERS | OMEROS CORPORATION | 2019-06-20 | — | — | US | disclosed |
| US-20190134055-A1 | Treatment of Addiction and Impulse-control Disorders Using PDE7 Inhibitors | OMEROS CORPORATION | 2019-05-09 | — | — | US | disclosed |
| EP-2139475-A2 | THE USE OF PDE7 INHIBITORS FOR THE TREATMENT OF MOVEMENT DISORDERS | Omeros Corporation (US) | 2010-01-06 | — | — | EP | disclosed |
| CN-101517056-A | Lubricating oil composition | IDEMITSU KOSAN CO (JP) | 2009-08-26 | — | — | CN | disclosed |
| CN-101511983-A | Lubricating oil composition for internal combustion engine | IDEMITSU KOSAN CO (JP) | 2009-08-19 | — | — | CN | disclosed |
| CN-100510033-C | Additive for lubricating oil and fuel oil, lubricating oil composition and fuel oil composition | IDEMITSU PETROCHEMICAL CO (JP) | 2009-07-08 | — | — | CN | disclosed |
| US-20080260643-A1 | USE OF PDE7 INHIBITORS FOR THE TREATMENT OF MOVEMENT DISORDERS | OMEROS CORPORATION (US) | 2008-10-23 | — | — | US | disclosed |
| WO-2008119057-A2 | THE USE OF PDE7 INHIBITORS FOR THE TREATMENT OF MOVEMENT DISORDERS | OMEROS CORPORATION (US) | 2008-10-02 | — | — | WO | disclosed |
| CN-1748022-A | Additive for lubricating oil and fuel oil, lubricating oil composition and fuel oil composition | IDEMITSU KOSAN CO (JP) | 2006-03-15 | — | — | CN | disclosed |
| WO-2002040449-A1 | DIHYDROISOQUINOLINES AS NOVEL PHOSPHODIESTERASE INHIBITORS | ALTANA PHARMA AG (DE) | 2002-05-23 | — | — | WO | disclosed |
| US-6262302-B1 | ALZHEIMER'S DISEASE | ELAN PHARMACEUTICALS, INC. | 2001-07-17 | — | — | US | disclosed |
| US-5663164-A | CEPHALOSPORIN ANTIBIOTICS AS BACTERICIDES | ROUSSEL UCLAF (FR) | 1997-09-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080260643-A1 | USE OF PDE7 INHIBITORS FOR THE TREATMENT OF MOVEMENT DISORDERS | PARK7, PDE7B, PDE7A | POLB 1493/4885CYP4F2 4491/4885CYP4A11 3370/4885 |
| US-11207275-B2 | Treatment of addiction and impulse-control disorders using PDE7 inhibitors | PDE7B, PDE4C, PDE4A | POLB 1466/4885CYP4F2 3185/4885CYP4A11 2212/4885 |
| US-20230110784-A1 | TREATMENT OF ADDICTION AND IMPULSE-CONTROL DISORDERS USING PDE7 INHIBITORS | PDE7B, PDE4C, PDE4A | POLB 1466/4885CYP4F2 3185/4885CYP4A11 2212/4885 |
| US-20190134055-A1 | Treatment of Addiction and Impulse-control Disorders Using PDE7 Inhibitors | PDE7B, PDE4C, PDE4A | POLB 1466/4885CYP4F2 3185/4885CYP4A11 2212/4885 |
| US-20190183824-A1 | USE OF PDE7 INHIBITORS FOR THE TREATMENT OF MOVEMENT DISORDERS | PARK7, PDE7B, PDE7A | POLB 1493/4885CYP4F2 4491/4885CYP4A11 3370/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.